The Prognostic Role of miR-31 in Colorectal Cancer: The Results of a Meta-Analysis of 4720 Patients

References

• Siegel RL , MillerKD , GodingSauer Aet al. Colorectal cancer statistics, 2020. CA Cancer J. Clin.70(3), 145–164 (2020).
   PubMed Web of Science ®Google Scholar
• Van Der Jeught K , XuHC , LiYJ , LuXB , JiG. Drug resistance and new therapies in colorectal cancer. World J. Gastroenterol.24(34), 3834 (2018).
   PubMed Web of Science ®Google Scholar
• Siomi H , SiomiMC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell38(3), 323–332 (2010).
   PubMed Web of Science ®Google Scholar
• Angius A , PiraG , ScanuAMet al. MicroRNA-425-5p expression affects BRAF/RAS/MAPK pathways in colorectal cancers. Int. J. Med. Sci.16(11), 1480–1491 (2019).
   PubMed Web of Science ®Google Scholar
• Hsu H-H , KuoWW , ShihHNet al. FOXC1 regulation of miR-31-5p confers oxaliplatin resistance by targeting LATS2 in colorectal cancer. Cancers11(10), 1576 (2019).
   PubMed Web of Science ®Google Scholar
• Ito M , MitsuhashiK , IgarashiHet al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int. J. Cancer135(11), 2507–2515 (2014).
   PubMed Web of Science ®Google Scholar
• Eizuka M , OsakabeM , SatoAet al. Dysregulation of microRNA expression during the progression of colorectal tumors. Pathol. Int.70(9), 633–643 (2020).
   PubMed Web of Science ®Google Scholar
• Liu G , LiB. Role of miRNA in transformation from normal tissue to colorectal adenoma and cancer. J. Cancer Res. Ther.15(2), 278 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang J , RajuGS , ChangDW , LinSH , ChenZ , WuX. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Cancer124(4), 785–796 (2018).
   PubMed Web of Science ®Google Scholar
• Yu T , MaP , WuD , ShuY , GaoW. Functions and mechanisms of microRNA-31 in human cancers. Biomed. Pharmacother.108, 1162–1169 (2018).
   PubMed Web of Science ®Google Scholar
• Moghadamnia F , GhoraeianP , MinaeianS , TalebiA , FarsiF , AkbariA. MicroRNA expression and correlation with mRNA levels of colorectal cancer-related genes. J. Gastrointest. Cancer51(1), 271–279 (2020).
   PubMed Web of Science ®Google Scholar
• Eneh S , HeikkinenS , HartikainenJMet al. MicroRNAs associated with biological pathways of left-and right-sided colorectal cancer. Anticancer Res.40(7), 3713–3722 (2020).
   PubMed Web of Science ®Google Scholar
• Peng H , WangL , SuQ , YiK , DuJ , WangZ. MiR-31-5p promotes the cell growth, migration and invasion of colorectal cancer cells by targeting NUMB. Biomed. Pharmacother.109, 208–216 (2019).
   PubMed Web of Science ®Google Scholar
• Siskova A , CervenaK , KralJ , HuclT , VodickaP , VymetalkovaV. Colorectal adenomas–genetics and searching for new molecular screening biomarkers. Int. J. Mol. Sci.21(9), 3260 (2020).
   PubMed Web of Science ®Google Scholar
• Mi B , LiQ , LiT , LiuG , SaiJ. High miR-31-5p expression promotes colon adenocarcinoma progression by targeting TNS1. Aging12(8), 7480 (2020).
   PubMedGoogle Scholar
• Slattery ML , PellattAJ , LeeFYet al. Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer. Oncotarget8(48), 83845–83859 (2017).
   PubMedGoogle Scholar
• Anandappa G , LampisA , CunninghamDet al. Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol.37(4), 548 (2019).
   Web of Science ®Google Scholar
• Farace C , PisanoA , Griñan-LisonCet al. Deregulation of cancer-stem-cell-associated miRNAs in tissues and sera of colorectal cancer patients. Oncotarget11(2), 116–130 (2020).
   PubMedGoogle Scholar
• Dienstmann R , VermeulenL , GuinneyJ , KopetzS , TejparS , TaberneroJ. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer17(2), 79–92 (2017).
   PubMed Web of Science ®Google Scholar
• Dienstmann R , SalazarR , TaberneroJ. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am. Soc. Clin. Oncolo. Ed. Book35(1), e149–e156 (2015).
   Google Scholar
• Cutsem EV , LenzH-J , KohneCet al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol.33(7), 692–700 (2015).
   PubMed Web of Science ®Google Scholar
• Peeters M , KarthausM , RiveraF , TerweyJH , DouillardJY. Panitumumab in metastatic colorectal cancer: the importance of tumour RAS status. Drugs75(7), 731–748 (2015).
   PubMed Web of Science ®Google Scholar
• Peterson J , WelchV , LososM , TugwellP. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute1–12 (2011).
   Google Scholar
• Rahmani J , Kord‐VarkanehH , HekmatdoostAet al. Body mass index and risk of inflammatory bowel disease: a systematic review and dose‐response meta‐analysis of cohort studies of over a million participants. Obes. Rev.20(9), 1312–1320 (2019).
   PubMed Web of Science ®Google Scholar
• Strippoli A , CocomazziA , BassoMet al. c-MYC expression is a possible keystone in the colorectal cancer resistance to EGFR inhibitors. Cancers12(3), 638 (2020).
   PubMed Web of Science ®Google Scholar
• Pugh S , ThiébautR , BridgewaterJet al. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the new EPOC trial. Oncotarget8(55), 93856–93866 (2017).
   PubMedGoogle Scholar
• Mlcochova J , Faltejskova-VychytilovaP , FerracinMet al. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget6(36), 38695–38704 (2015).
   PubMedGoogle Scholar
• Manceau G , ImbeaudS , ThiebautRet al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res.20(12), 3338–3347 (2014).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P , GrisoniML , HeinemannVet al. Validation of miR-31-3p expression to predict cetuximab efficacy when used as first-line treatment in RAS wild-type metastatic colorectal cancer. Clin. Cancer Res.25(1), 134–141 (2019).
   PubMed Web of Science ®Google Scholar
• Eriksen AHM , SørensenFB , AndersenRF , JakobsenA , HansenTF. Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. Oncol. Lett.14(1), 201–209 (2017).
   PubMed Web of Science ®Google Scholar
• Caramés C , CristobalI , MorenoVet al. Microrna-31 emerges as a predictive biomarker of pathological response and outcome in locally advanced rectal cancer. Internat. J. Mol. Sci.17(6), (2016).
   PubMed Web of Science ®Google Scholar
• Kubota N , TaniguchiF , NyuyaAet al. Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncol. Lett.19(4), 2685–2694 (2020).
   PubMed Web of Science ®Google Scholar
• Yang MH , YuJ , ChenNet al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS ONE8(12), e85353 (2013).
   PubMed Web of Science ®Google Scholar
• Nosho K , IgarashiH , NojimaMet al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis35(4), 776–783 (2014).
   PubMed Web of Science ®Google Scholar
• Mitsuhashi K , NoshoK , IgarashiHet al. MicroRNA-31 may predict response in patients with metastatic colorectal cancer treated with anti-EGFR therapy. Gastroenterology146(5), S329–S330 (2014).
   Web of Science ®Google Scholar
• Li Y , XinS , WuHet al. High expression of microRNA-31 and its host gene LOC554202 predict favorable outcomes in patients with colorectal cancer treated with oxaliplatin. Oncol. Rep.40(3), 1706–1724 (2018).
   PubMed Web of Science ®Google Scholar
• Igarashi H , KuriharaH , MitsuhashiKet al. Association of microRNA-31-5p with clinical efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer. Ann. Surg. Oncol.22(8), 2640–2648 (2015).
   PubMed Web of Science ®Google Scholar
• Brenner H , KloorM , PoxC. Colorectal cancer. Lancet383, 1490–1502 (2014).
   PubMed Web of Science ®Google Scholar
• Jung G , Hernández-IllánE , MoreiraL , BalaguerF , GoelA. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat. Rev. Gastroenterol. Hepatol.17(2), 111–130 (2020).
   PubMed Web of Science ®Google Scholar
• Pourakbari R , MousavishenasMH , KamraniAet al. Identification of genes and miRNAs associated with angiogenesis, metastasis, and apoptosis in colorectal cancer. Gene Rep.18, 100552 (2020).
   Web of Science ®Google Scholar
• Zhang WW , MingXL , RongYet al. Diagnostic value investigation and bioinformatics analysis of miR-31 in patients with lymph node metastasis of colorectal cancer. Anal. Cell. Pathol.2019, 9740475, (2019).
   Web of Science ®Google Scholar
• Bandrés E , CubedoE , AgirreXet al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer5(1), 1–10 (2006).
   PubMedGoogle Scholar
• Cui QJ . Significance of miR-27a and miR-31 in early diagnosis and prognosis of colorectal cancer. Oncol. Lett.18(3), 3092–3096 (2019).
   PubMed Web of Science ®Google Scholar
• Fakih MG . Metastatic colorectal cancer: current state and future directions. J. Clin. Oncol.33(16), 1809–1824 (2015).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB , BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Anandappa G , LampisA , CunninghamDet al. miR-31-3p Expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective Phase II PROSPECT-C trial. Clin. Cancer Res.25(13), 3830–3838 (2019).
   PubMed Web of Science ®Google Scholar
• Sur D , CainapSS , BurzCet al. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs? J. B.U.ON. 24(5), 1739–1746 (2019).
   Google Scholar
• Slattery ML , HerrickJS , MullanyLEet al. Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. Mod. Pathol.29(8), 915–927 (2016).
   PubMed Web of Science ®Google Scholar
• Lundberg IV , WikbergML , LjuslinderIet al. MicroRNA expression in KRAS-and BRAF-mutated colorectal cancers. Anticancer Res.38(2), 677–683 (2018).
   PubMed Web of Science ®Google Scholar